Cargando…
G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
GA trial is registered under EudraCT#: 2013-001639-38.
Autores principales: | Stopka, Tomáš, Minařík, Lubomír, Dusilková, Nina, Pešta, Michal, Kulvait, Vojtěch, Špaček, Martin, Zemanová, Zuzana, Kalousová, Marta, Jonášová, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262924/ https://www.ncbi.nlm.nih.gov/pubmed/35798720 http://dx.doi.org/10.1038/s41408-022-00698-2 |
Ejemplares similares
-
Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders
por: Polgarova, Kamila, et al.
Publicado: (2017) -
PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022) -
Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways
por: Minařík, Lubomír, et al.
Publicado: (2022) -
The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
por: Bhatt, Anjali, et al.
Publicado: (2022) -
Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)